Online inquiry

IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11563MR)

This product GTTS-WQ11563MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ11563MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2380MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 102
GTTS-WQ8932MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ15755MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ8607MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ14638MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ14496MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA RYI-018
GTTS-WQ11397MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ6858MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DX-2930
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW